Exenatide twice daily: Analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index

Postgraduate Medicine

Volumn 124, Issue 4, 2012, Pages 21-32

  Pencek, Richard ^a   Blickensderfer, Amy ^a   Li, Yan ^a   Brunell, Steven C ^a   Anderson, Pamela W ^b  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b Lilly USA   (United States)

Author keywords

Exenatide; GLP 1; Subgroups; Type 2 diabetes

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; LIPID; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; PEPTIDE; VENOM;

ADULT; AGE; AGED; APPETITE; ARTICLE; ASIAN; BODY MASS; CAUCASIAN; CONTROLLED STUDY; DISEASE DURATION; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; GENDER; GLUCOSE BLOOD LEVEL; HEADACHE; HISPANIC; HUMAN; HYPOGLYCEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; RACE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; BLOOD; DIABETES MELLITUS; DRUG ADMINISTRATION; DRUG POTENTIATION; ETHNOLOGY; SEX DIFFERENCE; TREATMENT OUTCOME;

AGE FACTORS; BLOOD GLUCOSE; BODY MASS INDEX; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PEPTIDES; RETROSPECTIVE STUDIES; SEX FACTORS; TREATMENT OUTCOME; VENOMS;

EID: 84871710499     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.07.2567     Document Type: Article

References (31)

1. BYETTA® (exenatide) injection [package insert]. San Diego, CA: Amlyin Pharmaceuticals, Inc; 2010.
2. Centers for Disease Control and Prevention. National diabetes fact sheet, 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed February 28, 2011.
3. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628-2635.
4. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092-1100.
5. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143(8):559-569.
6. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083-1091.
7. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29(11):2333-2348.
8. Zinman B, Hoogwerf BJ, Durán García S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146(7):477-485.
9. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448-1460.
10. Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long acting insulin to achieve glycemic control with minimal weight gain in patients with type 2 diabetes: results of Helping Evaluate Exenatide in patients with diabetes compared to Long-Acting insulin (HEELA) study. Diabetes Obes Metab. 2009;11(12):1153-1162.
11. Gao Y, Yoon KH, Chuang LM, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract. 2009;83(1):69-76.
12. Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, Brodows RG. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J. 2009;56(3):415-424.
13. Apovian CM, Bergenstal RM, Cuddihy RM, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med. 2010;123(5):e9-e17.
14. Liutkus J, Rosas Guzman J, Norwood P, et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab. 2010;12(12):1058-1065.
15. Gallwitz B, Böhmer M, Segiet T, et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care. 2011;34(3):604-606.
16. Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol. 2010;9(6):6.
17. DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC. Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care. 2010;33(5):951-957.
18. Kadowaki T, Namba M, Imaoka T, et al. Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J Diabetes Invest. 2011;2:210-217.
19. Nelson JM, Dufraux K, Cook PF The relationship between glycemic control and falls in older adults. J Am Geriatr Soc. 2007;55(12): 2041-2044.
20. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
21. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab. 2003;5(3):163-170.
22. Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.Drugs. 2002;62(12):1805-1837.
23. Erdmann E, Charbonnel B, Dormandy J, et al. Pioglitazone treatment in patients with type 2 diabetes and a history of myocardial infarction: subgroup analyses from PROactive stratified by gender, age, and duration of diabetes. Presented at: World Conference of Cardiology; September 2-6, 2006; Barcelona, Spain.
24. Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab. 2007;9(1):31-38.
25. Davidson JA, Lacaya LB, Jiang H, et al. Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: a post hoc analysis of clinical trials in type 2 diabetes mellitus. Endocr Pract. 2010;16(5):818-828.
26. Buysschaert M, Preumont V Oriot PR, et al; UCL Study Group for Exenatide. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab. 2010;36(5):381-388.
27. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007;29(1):139-153.
28. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24(1):275-286.
29. Shomali M, Hale P, Zdravkovic M. Liraglutide, a once-daily human GLP-1 analog, improves glycemic control more than glimepiride in African American or black individuals with type 2 diabetes. Presented at: 114th National Medical Association Annual Convention and Scientific Assembly; July 25-29, 2009; Las Vegas, NV
30. Yang W, Chen L, Ji Q, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial. Diabetes Obes Metab. 2011; 13(1):81-88.
31. Forti A, Garcia EG, Yu MB, Jimenez MC, Brodows RG, Oliveira JH. Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes. Curr Med Res Opin. 2008;24(9):2437-2447.